The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

The EGFR/PI3K/Akt/mTOR signaling pathway is activated in many cancers including glioblastoma, yet mTOR inhibitors have largely failed to show efficacy in the clinic. Rapamycin promotes feedback activation of Akt in some patients, potentially underlying clinical resistance and raising the need for al...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Guo, Deliang, Hildebrandt, Isabel J., Prins, Robert M., Soto, Horacio, Mazzotta, Mary M., Dang, Julie, Czernin, Johannes, Shyy, John Y.-J., Watson, Andrew D., Phelps, Michael, Radu, Caius G., Cloughesy, Timothy F., Mischel, Paul S.
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2009
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2714280/
https://ncbi.nlm.nih.gov/pubmed/19625624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0906606106
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items